NEW YORK (GenomeWeb) – Invitae said after the close of the market on Monday that it plans to offer $50 million in shares of its common stock in a public offering.

Based on a stock price of $7.02 per share, the last reported sale price of its stock on March 23, Invitae said in a prospectus filed with the US Securities and Exchange Commission that it anticipates offering 7,122,507 shares. The company also plans to give underwriters a 30-day option to purchase up to an additional $7.5 million of shares of its common stock at the public offering price.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.